Breaking News

Trials & Filings in Brief: Jan. 9, 2014

By Gil Roth | January 9, 2014

Acasti, AZ, BMS, Celator, DiaMedica, GSK, Intercept, Senesco, Vertex

Phase I
DiaMedica completes MAD trial . . . read more

Senesco begins dosing in new cohort . . . read more

Phase II
Intercept halts NASH trial after hitting primary endpoint . . . read more

Vertex posts initial HCV data . . . read more

Phase III
Celator hits 50% enrollment in AML trial . . . read more

Approvals
AZ/BMS diabetes drug approved . . . read more

GSK cancer combo get accelerated approval . . . read more

Filings
Acasti IND cleared by FDA . . . read more

blog comments powered by Disqus